Adjuvant Therapy for Localized High-Risk Renal Cell Carcinoma

Area of Science:

• Oncology
• Nephrology
• Clinical Trials

Background:

• Renal cell carcinoma (RCC) is a common kidney cancer.
• Localized RCC is often treated with surgical resection.
• Preventing cancer recurrence after surgery is a clinical challenge.

Purpose of the Study:

• To review the efficacy of adjuvant therapies in preventing recurrence of localized renal cell carcinoma (RCC) after resection.
• To evaluate the impact of tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors in the adjuvant setting for RCC.

Main Methods:

• Systematic review of clinical trials investigating adjuvant therapies for localized renal cell carcinoma.
• Analysis of studies focusing on TKIs and mTOR inhibitors as adjuvant treatments.
• Examination of disease-free survival (DFS) and overall survival (OS) data from relevant trials.

Main Results:

• Most adjuvant therapy trials for localized RCC, primarily using TKIs and mTOR inhibitors, showed no significant benefit.
• One trial reported a marginal improvement, but overall survival was not enhanced.
• Current evidence does not support the use of these targeted therapies in the adjuvant setting for localized RCC.

Conclusions:

• Adjuvant tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors have not demonstrated efficacy in preventing recurrence for localized renal cell carcinoma post-resection.
• Further research may be needed, but current data suggest these agents are not beneficial in this specific clinical context.
• The focus remains on optimizing surgical outcomes and surveillance for localized RCC.